Table 1 Patient demographic and baseline clinical characteristics (including all on- and off-drug data)
From: Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
TTP488 20 mg/day | TTP488 5 mg/day | Placebo | |
|---|---|---|---|
(n = 135) | (n = 131) | (n = 133) | |
Age (years) | 73.0 ± 9.0 | 73.6 ± 8.8 | 72.2 ± 9.6 |
Sex (% women) | 61 | 53 | 57 |
Race | |||
White | 128 | 120 | 125 |
Education (years) | 15.0 ± 3.0 | 14.8 ± 2.8 | 15.3 ± 2.8 |
MMSE | 19.9 ± 3.6 | 20.8 ± 3.5 | 20.5 ± 3.4 |
Mild (MMSE ≥20), n(%) | 71 (53%) | 84 (64%) | 81 (61%) |
Moderate (MMSE < 20), n(%) | 64 (47%) | 47 (36%) | 51 (39%) |
ADAS-cog | 24.9 ± 9.7 | 24.4 ± 9.8 | 24.1 ± 9.6 |
CDR-sb | 5.7 ± 2.9 | 5.6 ± 2.7 | 6.0 ± 2.8 |
ADCS-ADL | 61.3 ± 12.9 | 61.4 ± 12.3 | 59.9 ± 12.8 |
NPI | 7.9 ± 10.5 | 7.7 ± 10.3 | 8.6 ± 10.4 |
APOE e4+status, n (%) | 62 | 65 | 74 |
E2/E3 | 3 (2.3%) | 5 (4.2%) | 1 (0.9%) |
E2/E4 | 7 (5.4%) | 2 (1.7%) | 2 (1.7%) |
E3/E3 | 46 (35.7%) | 36 (30.5%) | 30 (25.6%) |
E3/E4 | 47 (36.4%) | 53 (44.9%) | 59 (50.4%) |
E4/E4 | 26 (20.2%) | 20 (16.9%) | 25 (21.4%) |
Unknown/Missing | 6 | 15 | 16 |
AchEI use, n(%) | 134 (99%) | 129 (98%) | 132 (100%) |
Memantine use, n (%) | 92 (68%) | 87 (66%) | 96 (73%) |